Topic:

M&A

Latest Headlines

Latest Headlines

Mylan challenges Teva to put up a bid--or shut up and let it buy Perrigo

Clock's ticking, Teva, as far as deal target Mylan's concerned. The Israeli drugmaker needs to either "stop playing games" and turn its $40 billion approach into a formal bid--or walk.

Juno snaps up an antibody biotech amid CAR-T horse race

Juno Therapeutics, at work on immune system-harnessing cancer treatments, bought up a small Massachusetts biotech to further flesh out its arsenal of technologies, picking up a new discovery platform as it races toward late-stage trials.

Steris and Synergy to contest fed's plans to block their merger

Steris and Synergy said they will fight the U.S. Federal Trade Commission's plan to prevent their $1.9 billion merger, which would create a global powerhouse in the medical device sterilization sector.

Look for orphan drugs to keep fueling M&A, Moody's says

Orphan drugs are attractive to make thanks to premium pricing prospects, limited competition and regulatory perks. But those factors also make them attractive to buy, and they'll continue to spur M&A activity in the biopharma field, Moody's predicts.

UCB reportedly gets bids for Kremers Urban unit from Cipla and Lupin

After having to call off a $1.5 billion deal last year to sell its U.S.-based generics business, Belgium's UCB has new bidders for the unit that reportedly includes India's Cipla and Lupin.

Zimmer to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close

Zimmer already has clearances from regulators in Europe and Japan for its proposed $13.4 billion acquisition of Biomet. Now it's close to gaining the go-ahead from the U.S. Federal Trade Commission. Zimmer has disclosed that it has secured buyers for three U.S. businesses to satisfy FTC requests: Zimmer Unicompartmental High-Flex Knee System assets, Biomet Discovery Elbow System assets and Cobalt bone cement assets.

Betting on Pfizer merger--or CEO goodbye--traders go bullish on Glaxo

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.

Bayer chief may plow spinoff cash into animal health buys

Bayer has seen many an M&A opportunity come and go when it comes to bolstering its animal health unit. But once it jettisons its plastics unit--a move that could generate some extra dough--it might finally be ready to strike a deal.

Buzz: Cellectis could be in line for a $1.6B Pfizer buyout

Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.

France's Labco sells to Cinven for $1.3B after pumping brakes on IPO

French medical diagnostics outfit Labco is selling out to U.K. private equity firm Cinven for €1.2 billion ($1.3 billion), shifting gears after abandoning its previously announced IPO.